Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes

Clinical Immunology

Volumn 127, Issue 2, 2008, Pages 138-143

  Sanda, Srinath ^a   Roep, Bart O ^b   von Herrath, Matthias ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

ELISPOT; FoxP3; Honeymoon; IL 10; Partial remission; Type 1 diabetes

Indexed keywords

GLUCOSE; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GLYCEMIC CONTROL; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; BLOOD GLUCOSE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; PREDICTIVE VALUE OF TESTS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25;

EID: 41749098274     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.12.003     Document Type: Article

References (11)

1. Roep B.O. T-cell response to autoantigens in IDDM. The search for the Holy Grail. Diabetes 45 (1996) 1147-1156
2. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann. Intern. Med. 128 7 (Apr 1 1998) 517-523
3. Muhammad B.J., Swift P.G., Raymond N.T., and Botha J.L. Partial remission phase of diabetes in children younger than age 10 years. Arch. Dis. Child. 80 4 (Apr 1999) 367-369
4. de Kleer I.M., Wedderburn L.R., Taams L.S., Patel A., Varsani H., Klein M., de Jager W., Pugayung G., Giannoni F., Rijkers G., Albani S., Kuis W., and Prakken B. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172 10 (May 15 2004) 6435-6443
5. Kriegel M.A., Lohmann T., Gabler C., Blank N., Kalden J.R., and Lorenz H.M. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 199 9 (May 3 2004) 1285-1291 Electronic publication 2004 Apr 26
6. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., and Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 1 (Jan 2005) 92-99
7. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., Roep B.O., and Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113 3 (Feb 2004) 451-463
8. Schloot N.C., Batstra M.C., Duinkerken G., De Vries R.R., Dyrberg T., Chaudhuri A., Behan P.O., and Roep B.O. GAD65-Reactive T cells in a non-diabetic stiff-man syndrome patient. J. Autoimmun. 12 4 (Jun 1999) 289-296
9. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., and Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 22 (May 30 2002) 1692-1698
10. Allan S.E., Crome S.Q., Crellin N.K., Passerini L., Steiner T.S., Bacchetta R., Roncarolo M.G., and Levings M.K. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19 4 (Apr 2007) 345-354 Electronic publication 2007 Feb 27
11. Alizadeh B.Z., Hanifi-Moghaddam P., Eerligh P., et al. Association of interferon-gamma and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. Clin. Exp. Immunol. 145 3 (Sep 2006) 480-484